Each NeuroPI module is prepared by distinguished faculty who are acknowledge leaders in their respective fields. Each module is composed of a set of multiple-choice items with preferred responses, instructions on how to collect cases to assess one’s practice, and resources for creating and implementing an effective improvement plan. Participants are able to compare their performance pre- and post-intervention to assess what changes have occurred in their practice.
Members: FREE $199.00*
*Free access is limited to one course at a time for eligible members.
- Diagnosis Criteria: DSP Symptoms and Signs.
- Diagnosis Criteria: Electrodiagnostic Studies.
- Laboratory Screening for Patients with DSP.
- Screening for Unhealthy Alcohol Use.
- Evaluation for Symptoms and Signs of Dysautonomia .
- Querying about Pain and Pain Interference with Function including Sleep.
- Querying about Falls for Patients with DSP.
- Patient Education Regarding Diagnosis and Treatment Options.
As a result of this program, the participant will determine individual practice gaps and address them through a performance improvement plan designed to improve competence, performance, and patient outcomes.
- Interpersonal Skills and Communication
- Medical Knowledge
- Patient Care
- Practice-based Learning and Improvement
Date of Release
April 8, 2016
This module is eligible for CME credits for three years from the release date.
NeuroPI Data Terms & Conditions
The American Academy of Neurology Institute (AANI) no longer requires You (NeuroPI and aan.com user) to provide full date of service (day/month/year); only year of service will be transmitted to and stored by AANI. All previously collected "day" and "month" from date of service records have been deleted from the AANI's NeuroPI database. Accordingly, for NeuroPI, AANI is not requesting or storing any "protected health information" or "limited data sets" as defined by the regulations issued under the Health Insurance Portability and Accountability Act of 1996. The patient data You submit to the AANI through NeuroPI is de-identified health information. You must track patients separately from NeuroPI. Within the NeuroPI modules, Your patients will be identified using a 4-digit patient code that You create. Any other identifying information is strictly prohibited. Please use the NeuroPI Patient Tracker to create Your 4-digit patient codes for Your personal reference. The NeuroPI Patient Tracker must not be shared with AANI.
The American Academy of Neurology Institute either owns or has permission to use all of the NeuroPI module content. You may use these modules for your personal, noncommercial use, but please send permissions requests for any other uses to NeuroPI@aan.com. All of the individual de-identified health information you submit to the AANI through NeuroPI is confidential. Your maintenance of certification ("MOC") credit information is transmitted to the American Board of Psychiatry and Neurology (ABPN) once You've completed a module. You can opt-out of this service in NeuroTracker. Please note, AANI is not a certifying board and members are encouraged to contact ABPN for the most up-to-date information on MOC requirements. You acknowledge that AANI is and shall be deemed the owner of all rights to the aggregate, de-identified data submitted to NeuroPI and subsets of the aggregate data, any and all reports based on the aggregate, de-identified data, and all trademarks and trade secrets arising from or reflected in NeuroPI (collectively, "Aggregate Data"), with the exception of your individual data. AANI has full and unencumbered rights to publish, disclose, distribute, market, sell, and create derivatives of, Aggregate Data in any form.
PUSHPA NARAYANASWAMI, MBBS, MD, FAAN
Assistant Professor of Neurology
Harvard Medical School/Beth Israel Deaconess Medical Center, Boston, MA
*Dr. Narayanaswami has received personal compensation for activities with Blue Cross Blue Shield of Massachusetts Pharmacy and Therapeutics Committee, Advanced Medical: Expert Medical Reports, and Boston Clinical Research Institute consultation for grant proposals. Dr. Narayanaswami has also received research support from MERZ Pharmaceuticals.
CHRISTOPHER GIBBONS, MD, MMSc
Assistant Professor of Neurology
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA
*Dr. Gibbons has received personal compensation for activities with Pfizer Inc. and Lundbeck as an advisory board member.
DONALD J. IVERSON, MD, FAAN
Humboldt Neurological Medical Group, Eureka, California
*Dr. Iverson has received personal compensation for participation in the Accorda Therapeutics speaker's bureau.
Program Manager, Online Learning
*Ms. Chamberlain has nothing to disclose.
+ Unlabeled Use of Products/Investigational Use Disclosure